市场调查报告书
商品编码
1403528
到 2030 年肛门测压系统的全球市场预测:按产品类型、医疗器材类型、最终用户和地区进行分析Anorectal Manometry Systems Market Forecasts to 2030 - Global Analysis By Product Type, Modality Type, End User and by Geography |
根据 Stratistics MRC 的数据,2023 年全球肛门测压系统市场规模为 7,822 万美元,预计到 2030 年将达到 1.4326 亿美元,预测期内复合年增长率为 9.03%。
肛门测压系统对于评估和诊断肛门区域相关状况至关重要。透过测量直肠和肛管的压力和肌肉功能,这些基于先进技术的系统为骨盆底功能障碍、大便失禁和便秘等疾病提供了重要的新见解。将带有压力感测器的导管插入直肠,以精确测量各种运动(例如耐力或放气)期间的肌肉收缩和协调性。
根据国家健康和营养检查调查 (NHANES) 的估计,仅在美国, 8.3% 的非收容人员患有大便失禁 (FI)。男性和女性的 FI 盛行率相似(7.7% vs. 8.9%)。
肛门测压系统的采用主要是由于久坐的生活方式、饮食变化和高龄化引起的肛门疾病的日益流行。越来越多的人出现骨盆底功能障碍、大便失禁和便秘等症状,需要准确的诊断工具进行早期疗育和有针对性的治疗计划。此外,肛门测压系统为尽可能最佳的患者照护提供准确的信息,人们越来越认识到这些疾病是导致患者发病的主要原因,这证明了这一点。它在提供诊断见解方面发挥着重要作用。
由于取得和维护肛门测压系统的初期成本较高,医疗机构面临财务挑战。运行和分析这些系统的输出需要专门的培训和技术知识,从而增加了资源需求。此外,在某些医疗保健环境中,实施这些系统的成本可能令人望而却步,尤其是那些资源和卫生预算有限的环境。
持续的技术进步带来了改善肛门测压系统的功能和易用性的机会。创新包括更好的导管设计、用户友好的介面以及与人工智慧 (AI) 整合以进行即时资料分析。此外,这种类型的改进可以简化流程,缓解医疗保健专业人员的学习曲线,并提高肛门测压的一般诊断准确性和有效性。
粪便检测、磁振造影(MRI) 和大肠是对肛门测压系统构成威胁的既定替代诊断方法。儘管出于患者舒适度、可及性和熟悉度等原因,医疗保健专业人员可能会继续青睐这些试验的技术,儘管它们各自有优点和缺点。此外,肛门测压系统的广泛普及受到替代诊断技术竞争的威胁。
肛门测压系统市场受到了 COVID-19大流行的各种影响。将资源集中在应对疫情上导致了製造、供应链和选择性医疗程序的早期中断,但后来凸显了市场的弹性和适应性。此外,由于疫情和远端医疗行业的迅速普及,人们对肛门健康的认识不断增强,从而导致向远端患者监护的转变,肛门测压系统有可能整合到远端医疗平台中。
预计独立式肛门测压系统将占据最大的市场占有率。其丰富的功能集和对详细诊断评估的适用性使这些系统成为专业配备的临床环境的可行选择。凭藉其强大的功能和先进的功能,独立系统可以在彻底的资料收集和分析至关重要的情况下处理各种诊断场景。此外,在传统临床环境中提供准确评估肛门功能的既定能力正在导致市场占有率的增加。
由于诊断程序的针对性方法以及外包专业测试的成长趋势,诊断中心产业预计将表现出最高的复合年增长率。诊断中心提供专业服务,等待时间更短,并配备肛门测压系统等最尖端科技,对寻求准确诊断评估的患者更具吸引力。此外,诊断中心是一个快速成长的行业,因为它们透过专门从事诊断来简化工作流程并提高效率。
预计肛门测压系统市场将占据北美地区的最大份额。该地区的优势包括先进医疗技术采用较早、胃肠道疾病患病率较高、医疗基础设施发达。此外,由于存在重要的市场参与者、持续的研发努力以及强大的法律规范,北美在肛门测压系统市场中占据了重要份额。
预计欧洲地区的复合年增长率最高。该地区显着的市场占有率归因于先进的诊断技术、先进的医疗基础设施和胃肠道疾病的高发病率。欧洲对医疗保健研究和开发的高度重视以及有利的报销政策使其成为肛门诊断创新的中心。此外,欧盟采用先进的医疗技术和提高肛门健康意识是推动该地区肛门测压系统显着增长的两个因素。
According to Stratistics MRC, the Global Anorectal Manometry Systems Market is accounted for $78.22 million in 2023 and is expected to reach $143.26 million by 2030 growing at a CAGR of 9.03% during the forecast period. Anorectal manometry systems are essential for the evaluation and diagnosis of conditions pertaining to the anorectal area. By measuring pressure and muscle function in the rectum and anal canal, these advanced technology-based systems offer important new insights into conditions like pelvic floor dysfunction, fecal incontinence, and constipation. A catheter equipped with pressure sensors is inserted into the rectum during the procedure to measure muscle contractions and coordination precisely during different exercises, like bearing down and squeezing.
According to the National Health and Nutrition Examination Survey's (NHANES) estimations, 8.3% of non-institutionalized people in the USA alone have faecal continence (FI). Men and women both had a similar prevalence of FI (7.7% vs. 8.9%).
Adoption of anorectal manometry systems is primarily driven by the rising prevalence of anorectal disorders, which are caused by sedentary lifestyles, dietary changes, and aging demographics. A growing number of people are experiencing conditions like pelvic floor dysfunction, fecal incontinence, and constipation, which make precise diagnostic tools necessary for early intervention and focused treatment plans. Additionally, anorectal manometry systems play a critical role in providing accurate diagnostic insights for the best possible patient care, as evidenced by the increasing recognition of these disorders as major contributors to patient morbidity.
Healthcare facilities face financial difficulties due to the high initial costs of acquiring and maintaining anorectal manometry systems. The resource intensity is increased by the requirement for specific training and technical know-how to run and analyze the output from these systems. Furthermore, in certain healthcare settings, especially those with limited resources or healthcare budgets, the cost of implementing these systems may be prohibitive.
Opportunities to improve the functionality and usability of anorectal manometry systems are presented by ongoing technological advancements. Innovations include better catheter designs, user-friendly interfaces, and integration with artificial intelligence (AI) for real-time data analysis. Moreover, improvements of this kind can simplify processes, lessen the learning curve for medical professionals, and raise the general diagnostic accuracy and effectiveness of anorectal manometry.
Defecagraphy, magnetic resonance imaging (MRI), and colonoscopy are among the well-established alternative diagnostic modalities that pose a threat to anorectal manometry systems. Healthcare professionals may continue to favor these tried-and-true techniques despite their own advantages and disadvantages due to things like patient comfort, accessibility, and familiarity. Additionally, the widespread use of anorectal manometry systems is threatened by competition from alternative diagnostic techniques.
The anorectal manometry systems market has been impacted by the COVID-19 pandemic in a number of ways. While lockdowns and the focus of resources on pandemic response caused disruptions in manufacturing, supply chains, and elective medical procedures in the early stages, the market's resilience and adaptability were brought to light in the later stages. Furthermore, anorectal manometry systems have the potential to be integrated into telehealth platforms due to the shift towards remote patient monitoring brought about by the pandemic's increased awareness of anorectal health and the telemedicine industry's rapid adoption.
It is projected that stand-alone anorectal manometry systems will command the largest market share. These systems have been the go-to option in clinical settings with specialized facilities because of their extensive feature set and suitability for in-depth diagnostic evaluations. With their robust capabilities and advanced functionalities, stand-alone systems can handle a wide range of diagnostic scenarios in situations where thorough data collection and analysis are critical. Moreover, their greater market share is a reflection of their well-established ability to provide accurate assessments of anorectal function in conventional clinical settings.
Due to the targeted approach to diagnostic procedures and the growing trend of outsourcing specialized tests, the diagnostic center segment is expected to have the highest CAGR. Diagnostic centers are more appealing to patients looking for accurate diagnostic evaluations because they offer specialized services with shorter wait times and are outfitted with cutting-edge technologies like anorectal manometry systems. Additionally, diagnostic centers are a rapidly growing segment due to their streamlined workflow and specialization in diagnostics, which enhance efficiency.
The market for anorectal manometry systems is expected to have the largest share in the North American region. The region's early adoption of cutting-edge medical technologies, high prevalence of gastrointestinal disorders, and well-established healthcare infrastructure are all contributing factors to its dominance. Furthermore, the substantial market share held by North America in the anorectal manometry systems market is further attributed to the existence of important market players, continuous research and development efforts, and a strong regulatory framework.
Europe region is projected to have the highest CAGR. The region's noteworthy market share can be attributed to its advanced diagnostic technologies, sophisticated healthcare infrastructure, and high incidence of gastrointestinal disorders. Europe is a center for innovation in anorectal diagnostics because of its dedication to healthcare R&D and its advantageous reimbursement policies. Moreover, the European Union's adoption of advanced medical technologies and growing consciousness of anorectal health are two factors driving the significant growth of anorectal manometry systems in the region.
Some of the key players in Anorectal Manometry Systems market include Laborie Medical Technologies, Medtronic plc, Sierra Scientific Instruments, Albyn Medical S.L., InnovaStar, MMS Medical Measurement Systems B.V., Oakworks Med, Schuster Medizin-Technik GmbH and Medspira.
In September 2023, Laborie Medical Technologies has entered a definitive agreement for the acquisition of medical device company Urotronic in a deal valued at up to $600m. As per the deal, Laborie will make an upfront cash payment of $255m to Urotronic. Urotronic is entitled to receive potential commercial and reimbursement milestone payments of up to an additional $345m.
In May 2023, Medtronic plc, a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch® device - a tubeless, wearable and fully disposable insulin delivery device.